Search results
Results From The WOW.Com Content Network
Tamsulosin is primarily used for benign prostatic hyperplasia (BPH) and to help with the passage of kidney stones. [13] [14] Tamsulosin, however, appears to be effective only for stones over 4 mm and less than 10 mm in size. [8] Tamsulosin is also used as an add-on treatment for acute urinary retention. People may void more successfully after ...
Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010. [4] In June 2011, the FDA approved a label change to warn of "Increased Risk of High-grade Prostate Cancer" from Jalyn. [5]
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
The Biopharmaceutics Classification System (BCS) is a system to differentiate drugs on the basis of their solubility and permeability. [1] This system restricts the prediction using the parameters solubility and intestinal permeability. The solubility classification is based on a United States Pharmacopoeia (USP) aperture.
This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the cerebrospinal fluid and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors.
Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. [3] [5]Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low levels is often the treatment goal in the management of advanced prostate cancer.
Treatment of multiple myeloma with daratumumab potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus). [16] Daratumumab frequently causes human cytomegalovirus (CMV) reactivation by an unknown mechanism. [17]
[7] [9] [10] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. [ 11 ] In January 2024, the FDA approved erdafitinib for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease ...